The relationships between different strains of mumps virus were established by determination of the sequence of the HN gene. They closely resemble those established from other portions of the genome~ suggesting that the viruses are not recombinants over the areas examined. The relationships were consistent with those established by reaction with monoclonal antibodies raised against the Urabe strain, which has a similar antigenic structure to previously studied laboratory strains, and largely consistent with the specificity of the serological response of naturally infected or vaccinated human subjects.
Introduction
Mumps is a common childhood infection whose clinical symptoms include parotitis, and in the absence of effective vaccination programmes is one of the most common causes of viral meningitis. The causative agent is a member of the genus Rubulavirus, subfamily Paramyxovirinae, family Paromyxoviridae, and infection is believed to confer lifelong immunity.
Currently used vaccines take the form of live attenuated strains which were all derived empirically by laboratory passage of wild-type virus (Buynak & Hilleman, 1966; Girl& et aI., 1986; Yaminishi et al., 1970) . Limited studies in animals were undertaken, but as there is no convincing animal model for mumps, the safety and efficacy of vaccines in use depends entirely on consistency of production and clinical trials. The Urabe vaccine strain was implicated in neurological complications following vaccination, initially by epidemiological criteria (Balraj & Miller, 1995) . This laboratory, and others, demonstrated that it was possible to identify a strain as Urabelike by sequencing limited portions of the genome (Forsey et al., 1990; Yamada et al., 1990; Brown et al., 1991; Afzal et al., 1993 Afzal et al., , 1994 . Isolates from cerebrospinal fluid of children undergoing hospital investigation were shown to be related to Author for correspondence: P. D. Minor. Fax +44 1707 646730.
The nucleotide sequences reported in this paper have been submitted to the EMBL database and assigned the accession numbers X93176-X93181 and X98874-X98875.
the Urabe vaccine strain, which, as a result, has now been replaced in the UK by the Jeryl Lynn vaccine strain. Virus related to Jeryl Lynn has not been isolated from cases of suspected meningitis. A third vaccine strain, Rubini, is used in Switzerland and is also considered safe and effective (Glrlck et a]., 1986). The basis for the attenuation of any of the live mumps vaccine strains is very poorly understood, and while immunity is assessed by measurement of antibody levels, of which neutralizing antibodies are regarded as the most specific and reliable, the immunological basis for protection from disease is not clear.
Previous sequencing studies have identified relationships between strains available in this laboratory including wild-type and vaccine related isolates, and the work described here extends the comparison to the HN gene. As the HN protein is a major site for neutralizing antibodies we have also studied the neutralization of the sequenced strains by a panel of monoclonal antibodies and polyclonal human sera following either wild-type infection or vaccination with different strains of mumps virus. The genetic relationships established by sequencing of the HN gene are the same as those resulting from sequences of other portions of the genome, and consistent with the reactions with monoclonal antibodies, and are reflected to some extent in the reactions with human sera.
Methods
• Viruses. The Rubini vaccine strain was sequenced directly from unpassaged commercial vaccine prepared by the manufacturers (Swiss Serum Institute) on human diploid cells (MRC-5). All other viruses were grown on Vero cells at NIBSC, and included the Enders strain (kindly supplied by B. K. Rima, The Queen's University of Belfast, UK), the Urabe strain grown from a commercial bulk vaccine, the two distinct subpopulations of the Jeryl Lynn vaccine strain, JL2 and JL5 , and the wild-type isolates Ed4.3 and Lol (Forsey et aI., 1990 ). An additional strain designated Eurol was also sequenced; this strain grew from an inoculum believed to be of the Enders strain (Forsey et aI., 1990) and its true provenance is unknown. All antigenic analysis involved stocks passaged on Vero cells at NIBSC.
• Nucleotide sequencing. RNA was extracted from infected tissue culture supernatants using guanidine isothiocyanate (Chomczynski & Sacchi, 1987) . Reverse transcription was carried out by using primer PI (message sense in the SH gene at positions 3272-3295), 5' GATCAA-TCACTCTAGAAAGATCGC 3' (Elliot et at., 1989) . Subsequent amplification by PCR was performed by using the primers P1 and P2 (genome sense in the L gene at position 7-30), 5' GTATCTCATTTA-GGCCCGCCATTC 3' (Okazaki et at., 1992) under the following conditions: 94 °C for 1 min, 48 °C for 0'5 min, 72 °C for 2"5 min, 30 cycles, with a final extension at 72 °C for 8"5 rain. The products were purified with Prep-A-Gene (Bio-Rad) and subjected to direct cyclic DNA sequencing. A dendrogram of sequence relatedness was generated by the Growtree program (GCG software) with UPGMA (unweighted pair group method using arithmetic averages).
• Monoclonal antibodies. BALB/c mice were immunized at 12, 18 and 20 weeks with approximately 320 haemagglutinating (HA) units of purified Urabe strain virus grown on Vero cells (Orvell, I976) . Three days after the last immunization, spleens were taken and Iymphocytes fused with the mouse myeloma line NSO (Gerhard et al., 1980) . Fusions were screened by ELISA using wells sensitized with 2-16 HA units of virus; positive wells were cloned in soft agar and hybridomas grown as ascites in BALB/c mice. Antibodies were characterized by radioimmunoprecipitation, neutralization assays, haemagglutination inhibition (HI) and neuraminidase inhibition (NI) (Orvell & Grandien, 1982) . Variants were selected on Vero cells in FB6 tissue culture plates by incubation of the Urabe strain with the desired antibody at an appropriate dilution, usually 1:100, followed by plaque formation on Veto cells under an overlay also containing the antibody. Variants were grown up for further study in the presence of the same antibody.
• Neutralization assays. These were done as described by Mann et al. (1980) . Doubling dilutions of antibody were mixed with approximately 20 p.f.u, of virus in a final volume of I00 I~l in an FB24 tissue culture plate and incubated for 2 h at room temperature. Veto cells were then added, and incubation continued for another 4 h at 35 °C after which the tissue culture fluid was removed and the cell sheet was covered with I mI of MEM containing 3 % fetal calf serum and 0'8 % low viscosity carboxymethyl cellulose per well. The plates were stained with 0'5 % methylviolet after 7 days of incubation at 35 °C. The HI and NI assays were performed according to Orvell & Grandiens (1982) .
• Human sera. Sera were obtained from children within 12 months of receiving measles mumps rubella vaccine containing either the Urabe strain or the Jeryl Lynn strain of mumps virus. Sera were also obtained from unvaccinated blood donors aged between 18 and 65 in 1985.
Results

Nucleotide sequences of the HN gene
The complete HN gene sequences of the Urabe and Rubini vaccine strains, the two subpopulations of the Jeryl Lynn vaccine strain designated JL2 and JLS, the Enders strain and the wild-type strains designated Ed4.3, Lol and Eurol were determined and have been lodged with the EMBL nucleotide sequence database (accession numbers X93176-X93181, X98874-X98875). The deduced amino acid sequences are presented in Fig. 1 with those for RW (Waxham et al., 1983) , SBL-1 (K6vamees et al., 1989) and Miyahara (Takeuchi et al., 1989) .
The HN gene of all isolates was 1887 nucleotides long with a single open reading flame of 582 codons starting with an AUG at nucleotides 91-93, and terminating with a UGA at nucleotides 1837-1839. The consensus sequence ( Fig. 1 ) contained nine potential glycosylation sites (Asn-X-Thr or Asn-X-Ser) at codons 12-14, 127-129, 284-286, 329-331, 400-402, 448-450, 464-466, 507-509 and 514-516 . Those at 127-129 and 464-466 possess a cysteine as the variable residue and that at 514-516 a proline as the variable residue. These three sites may therefore not be glycosylated. The site at amino acids 12-14 was absent from Ed4.3, EuroI and Lol, while the site at amino acids 464-466 was absent from RW, JL2 and JLS.
A tree of the relatedness of the various isolates is shown in Fig. 2 . Three clusterings were readily identified, similar to those previously described (Yeo et al., 1993) consisting of JL2, JLS, SBL-1, Enders and Rubini (designated group A), Urabe, Miyahara and RW (designated group B) and the remainder (designated group C) comprising Lol, Ed4.3 and Euro 1. Groups B and C were more closely related to each other than either was to group A. The tree presented in Fig. 2 is essentially identical to that previously published based on the SH gene Yeo ef al., 1993; Ktinkel et al., 1995) except that RW is assigned to group B by its HN gene and to group C by its SH gene. Similar trees for the other strains have also been generated based on sequences of the Leader and N genes (M. A. Afzal, unpublished) , the M gene (Afzal et al., 1994) and the F gene (Forsey eta/., 1990) , implying that, for the viruses examined, any region of the genome giving sufficient resolution would be satisfactory for establishing relationships.
The Rubini strain is extremely closely related to the Enders strain, the HN gene differing by three bases at the nucleotide level (data not shown) and two residues at the amino acid level (Fig. 1 ). In contrast, the known American isolates JL2 and JL5 differed from each other by 59 bases and 16 amino acids, and the known UK isolates LoI and Ed4.3 by 24 bases and four amino acids. Not only are Rubini and Enders unexpectedly closely related for strains originating in Switzerland in 1974 and in the USA in 1945, but a very high proportion of the nucleotide changes observed result in a predicted amino acid change.
Characterization of monoclonal antibodies
Of 38 monoclonal antibodies prepared, i1 were shown by radio-immunoprecipitation, HI, NI and neutralization tests to recognize the HN protein. Eight were of high titre and were )-49~ * Antibodies were prepared as ascitic fluids. t Neutralization titre is the reciprocal of the antibody dilution required to neutralize 50% of the virus. $ HI titre is the reciprocal of the antibody dilution required to inhibit 50 % agglutination of 0"5 % turkey erythrocytes. § NI titre is the reciprocal of the antibody dilution required to inhibit neuraminidase activity by 50 %. studied further; their properties are summarized in Table 1 . Attempts to isolate mutants from the Urabe strain were made with all eight and were successful with three, as shown in Table  2 . Antibody 1648 selected a mutant (1648/V2/2) with a single amino acid substitution at residue 138 which was a leucine in the wild-type and a proline in the mutant. Antibody 1648, like antibodies 1637 and 1641 had NI but not HI activity. The mutant was neutralized by all antibodies of the panel other than 1648. Antibody 1689 selected a mutant (1689/V32/2) with a substitution at residue 359, which was a glutamine in the wild-type and an arginine in the mutant and also at amino acid 335, which was a glutamate in the wild-type and a lysine in the mutant. The mutant was also resistant to antibody 1721, and
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Analysis of wild-type isolates with monoclonal antibodies
The RW and Miyahara strains were not available, but the ability of the monoclonal antibodies to neutralize the other nine strains shown in Fig. I was investigated and the results are summarized in Table 3 . All antibodies neutralized the Urabe, Eurol, Ed4.3 and Lol strains, implying that they are antigenically closely related, while in contrast the remaining strains which made up the cluster designated group A were not neutralized by at least two of the panel. SBL-1, Enders, JL2 and Rubini were all resistant to neutralization by antibodies 1970 and 1711, and were the most closely related of the five strains of group A in terms of sequence. Antibody 1711 also failed to neutralize JL2 and JL5, and all isolates of group A differ from those of groups B and C at residue 372, the locus of one of the mutations selected by antibody 1711 from the Urabe strain. It is therefore possible that this amino acid forms part of the epitope recognized by 1711, although all members of group A also differ from groups B and C at residues 356, 474 and 577 as shown in Fig. 1 , and mutations in the resistant mutant occur at residues 251, 259, 335 and 464. Similarly, JL5 is the only member of group A to be neutralized by antibody 1970, and like all members of groups B and C, which are also neutralized by 1970, it possesses a glutamine instead of a proline at amino acid 354. Residue 354 may thus form part of the epitope recognized by antibody 1970.
Strains JL2 and JL5 are resistant to both 1689 and 1721 but do not have unique substitutions at, or near, residues 359 or 335 comparable to the resistant mutants selected from the Urabe strain by antibody 1689. The three antibodies having NI but not HI activity neutralized all strains examined. Amino acid differences in HN gene compared to Urabe 
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Analysis of isolates with human sera
Sera from 56 recipients of the Urabe vaccine strain, 42 recipients of the Jeryl Lynn vaccine strain and 51 unvaccinated blood donors were each assayed for virus neutralizing antibody with Jeryl Lynn from group A, Urabe from group B and Lol from group C. The results are summarized in Table 4 in terms of the number of sera having any detectable antibody and the geometric mean titres (GMT) of the positive samples.
The level of positivity was high in all cases. However, in the recipients of Urabe vaccine, marginally more were positive when assayed for the ability to neutralize the Urabe strain (96 %) than the Lol strain (93 %) or the Jeryl Lynn strain (80 %). Similarly, more of the sera from recipients of the Jeryl Lynn strain were positive when assayed against Jeryl Lynn (95 %) than either of the other strains (90 % each). Finally, all blood donor sera were positive when assayed with Lol (an isolate from the UK which is likely to resemble the wild-type UK strain with which they had originally been infected) while fewer were seropositive when assayed with either Urabe or Jeryl Lynn. These results suggest a strain-specific component in the immune response and are consistent with the reactivities with the monoclonal antibodies generated against the Urabe strain to the extent that antibodies generated in vaccinees by the Urabe strain appear to cross-react with Lol more effectively than with Jeryl Lynn.
However, the GMT for the positive sera were anomalous in that they were highest in all serum groups when the challenge strain was Urabe. The results for Jeryl Lynn and LoI were consistent with a strain-specific element in the response, however, and in the Urabe recipients titres were significantly :49! higher (P < 0"01, Wilcoxon rank test) when LoI, rather than ]eryl Lynn, was the challenge strain.
Discussion
Partial sequence comparisons in the HN gene have been used by others to distinguish strains of mumps virus (Brown et al., 1991) and the data reported here indicate that the relationships identified are essentially identical with those derived from sequences of other regions of the genome. This is evidence that none of the strains examined was a recombinant over the areas examined, and that any region of the genome giving adequate discrimination would be suitable for determining the relationship between strains. Three major lineages were identified. The Rubini vaccine strain was surprisingly closely related to the Enders strain, especially in view of the fact that the Rubini strain was isolated in Switzerland in 1974 (R. Glfick, personal communication) while the Enders strain was isolated in the USA in 1945. It is possible that an Enders-like strain was circulating in Switzerland 30 years after its first isolation in the USA, but it is also possible that the Rubini strain originated from the Enders strain in some way. This would not affect its use as a vaccine of proven clinical safety and efficacy. The Rubini and Enders strains are identical in other portions of the genome examined so far, including the Leader, N, M, F and SH genes Kfinkel et al., 1995 ; M. A. Afzal, unpublished) . It is of interest that, in general, the frequency of silent substitutions in regions encoding proteins between strains is far higher than that of coding substitutions, as expected if there are functional constraints on the variability of the proteins. For example, in the HN gene 43 of the 59 differences between JL2 and JL5 are silent, as are 20 of the 24 differences between Lol and Ed4.3. In contrast, three of the four differences in the HN gene between Enders and Rubini result in predicted amino acid changes and it is possible that they contribute to the major differences in growth characteristics observed between the two strains in vitro M.A. Afzal, unpublished) . This is the subject of further study.
Previous studies (Server et al., 1982; Rydbeck et al., 1986 ) have shown that monoclonal antibodies against the HN protein are able to distinguish different strains of mumps virus. Rydbeck et al. (1986) examined the reactions of eight monoclonal antibodies specific for the HN protein as well as a large number of antibodies with other specificities with nine wild-type isolates and demonstrated antigenic differences between isolates. The antibodies were raised against the SBL-I strain and two failed to react with isolates made in Stockholm, Iceland and Argentina after 1982. The antibodies studied here were raised against the Urabe vaccine strain and the specificity of neutralization of isolates was generally consistent with the relationships deduced from the sequence data. Thus the most distant lineage (group A) was less well neutralized than the other two. It was of interest that antibodies with NI but not HI activity were the most broadly reactive. Comparison of the sequences of mutants of the Urabe strain isolated for resistance to neutralization with monoclonal antibodies with those of non-neutralized wild-type strains suggested that in at least one case (monoclonal antibody 1711) amino acid differences consistent with resistance might be identified. The complexity of the antigenic structure of a protein is such that correlations of this kind would not be expected to be strictly reliable.
Antigenic relationships between strains were also observable to some extent with human sera from vaccinees or individuals infected with wild-type mumps virus, where a strain-specific element in the responses was seen. The effect was less striking than has been reported for antigenically variant measles isolates made over a 30 year period (Tamin et al., 1994) .
The results of neutralization tests with human sera challenged with Urabe were anomalous when the GMT of positive sera were considered. A strain-specific immune response would be expected to result in the highest GMT when the sera were challenged with the same virus which induced the immune response. In fact, the GMT were highest in all groups when Urabe was used as the challenge virus, which suggests that the stock used may be more readily neutralizable by polyclonal sera than that of the other strains, for example if it were neutralized non-specifically, or by lower avidity antibodies which were unable to affect other strains, or contained fewer defective interfering particles competing for antibodies. As neutralizing antibody titres are regarded as the most specific and satisfactory measure of immunity to mumps, the observation is potentially of practical importance and is the subject of further study.
